What we do
ANDA
Developing bioequivalent formulations of high barrier to entry products with significant development, legal and regulatory challenges. We are focused on targeting high-value solid oral and alternative dosage form ANDAs that are difficult to develop and that bring sustainable profitability.
505(b)(2)
Developing differentiated products by applying our ElectroNanospray (ENS) platform to improve the performance of existing drug products with poor solubility, low bioavailability, high food effect, or variable PK.
ENABLING
Enable formulations for preclinical development. Nanocopoeia is a formulation and process resource for the pharmaceutical industry. Nanocopoeia works with drug development companies to create efficient and effective ways to enable formulations of challenging new chemical entities and/or leverage existing libraries of compounds with known solubility issues but potentially significant commercial value.
The benefits
-
Improving Drugs
Improving drugs through spray science formulation of challenging APIs
-
Innovation
Novel technology platform
Uniform, small, amorphous particles -
Speed to Market
Spray science formulation prototyping
Rapid process optimization -
IP Opportunity
New intellectual property Lifecycle management
About us
-
History & Leadership
Nanocopoeia, LLC is a privately held specialty pharmaceutical company located in St. Paul, Minnesota.
-
Business Model
Improving drug performance.